[
    [
        {
            "time": "2018-04-17",
            "original_text": "How Analysts Rate JNJ after 1Q18 Earnings",
            "features": {
                "keywords": [
                    "Analysts",
                    "JNJ",
                    "1Q18",
                    "Earnings"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "How Analysts Rate JNJ after 1Q18 Earnings",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-04-25",
            "original_text": "Bristol-Myers Squibb’s 1Q18 Earnings Beat Wall Street Estimates",
            "features": {
                "keywords": [
                    "Bristol-Myers",
                    "Squibb",
                    "1Q18",
                    "Earnings",
                    "Beat",
                    "Wall Street",
                    "Estimates"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Bristol-Myers Squibb’s 1Q18 Earnings Beat Wall Street Estimates",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "What’s Johnson & Johnson’s Valuation after 1Q18 Earnings?",
            "features": {
                "keywords": [
                    "Johnson",
                    "&",
                    "Johnson",
                    "Valuation",
                    "1Q18",
                    "Earnings"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "What’s Johnson & Johnson’s Valuation after 1Q18 Earnings?",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-03-28",
            "original_text": "Novo Nordisk’s Victoza Could See High Growth in 2018",
            "features": {
                "keywords": [
                    "Novo",
                    "Nordisk",
                    "Victoza",
                    "High",
                    "Growth",
                    "2018"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Novo Nordisk’s Victoza Could See High Growth in 2018",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]